Total Payments
$2.3M
2024 Payments
$236,329
Companies
48
Transactions
1,996
Medicare Patients
3,541
Medicare Billing
$500,187
Payment Breakdown by Category
Other$1.5M (65.8%)
Consulting$674,048 (28.7%)
Travel$87,027 (3.7%)
Food & Beverage$41,439 (1.8%)
Education$99.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 581 | 65.1% |
| Consulting Fee | $674,048 | 92 | 28.7% |
| Travel and Lodging | $87,027 | 337 | 3.7% |
| Food and Beverage | $41,439 | 969 | 1.8% |
| Honoraria | $15,773 | 3 | 0.7% |
| Education | $99.93 | 12 | 0.0% |
| Unspecified | $0 | 2 | 0.0% |
Payments by Type
General
$2.3M
1,994 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sensible Medical Innovations Inc | $370,058 | 20 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $313,615 | 317 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $284,216 | 251 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $280,200 | 270 | $0 (2021) |
| Lilly USA, LLC | $184,924 | 139 | $0 (2024) |
| PFIZER INC. | $175,571 | 187 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $141,209 | 122 | $0 (2024) |
| Caption Health, Inc. | $120,026 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $113,502 | 76 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $95,263 | 54 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236,329 | 172 | Bayer Healthcare Pharmaceuticals Inc. ($46,888) |
| 2023 | $299,144 | 173 | Sensible Medical Innovations Inc ($54,582) |
| 2022 | $379,060 | 242 | Actelion Pharmaceuticals US, Inc. ($81,514) |
| 2021 | $273,945 | 198 | Sensible Medical Innovations Inc ($51,628) |
| 2020 | $235,450 | 220 | Boehringer Ingelheim Pharmaceuticals, Inc. ($36,002) |
| 2019 | $349,139 | 379 | Sensible Medical Innovations Inc ($90,717) |
| 2018 | $348,266 | 327 | Novartis Pharmaceuticals Corporation ($102,785) |
| 2017 | $225,230 | 285 | Novartis Pharmaceuticals Corporation ($88,692) |
All Payment Transactions
1,996 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $31.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,791.00 | General |
| Category: Cardio-renal | ||||||
| 12/05/2024 | iRhythm Technologies, Inc. | Zio monitor (Device), ZIO XT Patch | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $123.07 | General |
| Category: Cardio-renal | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,948.00 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: DIABETES | ||||||
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Sensible Medical Innovations Inc | ReDS system (Device) | Consulting Fee | Cash or cash equivalent | $36,000.00 | General |
| Category: ReDS system | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $19.78 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/07/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $79.79 | General |
| Category: DIABETES | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $204.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $113.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $98.33 | General |
| Category: DIABETES | ||||||
| 10/18/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $104.52 | General |
| Category: Cardiology | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/17/2024 | Sensible Medical Innovations Inc | ReDS system (Device) | Food and Beverage | Cash or cash equivalent | $54.31 | General |
| Category: ReDS system | ||||||
| 10/11/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,185.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,054.00 | General |
| Category: Cardio-renal | ||||||
| 10/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $182.91 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 826 | 1,562 | $403,690 | $100,454 |
| 2022 | 21 | 838 | 1,585 | $456,145 | $116,593 |
| 2021 | 21 | 854 | 1,780 | $521,188 | $135,002 |
| 2020 | 18 | 1,023 | 2,002 | $585,584 | $148,138 |
Total Patients
3,541
Total Services
6,929
Medicare Billing
$500,187
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 281 | $73,060 | $25,078 | 34.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 32 | 87 | $58,725 | $13,983 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 124 | 167 | $43,420 | $11,342 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 105 | $36,750 | $11,122 | 30.3% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 19 | 256 | $44,800 | $7,602 | 17.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 49 | $24,255 | $6,419 | 26.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 117 | 125 | $28,625 | $5,996 | 20.9% |
| 93460 | Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 14 | 14 | $16,940 | $3,847 | 22.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 52 | $9,360 | $3,046 | 32.5% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 23 | 25 | $11,250 | $2,413 | 21.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 17 | 22 | $5,830 | $1,910 | 32.8% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 13 | 16 | $12,650 | $1,306 | 10.3% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 16 | 16 | $5,200 | $1,295 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $4,740 | $1,110 | 23.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 119 | 140 | $6,160 | $841.84 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 16 | $2,800 | $785.41 | 28.1% |
| 93289 | Evaluation of single, dual, or multiple lead implantable defibrillator system | Facility | 2023 | 22 | 28 | $3,752 | $745.51 | 19.9% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2023 | 11 | 11 | $2,475 | $565.07 | 22.8% |
| 76376 | 3d radiographic procedure | Facility | 2023 | 39 | 41 | $1,599 | $288.59 | 18.0% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 30 | 31 | $5,425 | $244.72 | 4.5% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 14 | 14 | $804.00 | $188.86 | 23.5% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 16 | 18 | $2,790 | $169.20 | 6.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2023 | 17 | 21 | $1,365 | $120.60 | 8.8% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 15 | 15 | $915.00 | $35.25 | 3.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 47 | 183 | $123,525 | $30,728 | 24.9% |
About Dr. Daniel Bensimhon, MD
Dr. Daniel Bensimhon, MD is a Internal Medicine healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245293505.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Bensimhon, MD has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $236,329 received in 2024. These payments were reported across 1,996 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Bensimhon has provided services to 3,541 Medicare beneficiaries, totaling 6,929 services with total Medicare billing of $500,187. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Greensboro, NC
- Active Since 04/08/2006
- Last Updated 08/09/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1245293505
Products in Payments
- JARDIANCE (Drug) $463,749
- ELIQUIS (Drug) $312,072
- ENTRESTO (Drug) $266,860
- ReDS system (Device) $261,781
- UPTRAVI (Drug) $259,738
- Kerendia (Drug) $113,389
- FUROSCIX (Drug) $95,263
- FARXIGA (Drug) $73,649
- Caption Guidance (Device) $65,321
- ZIO Patch (Device) $51,139
- ZIO XT Patch (Device) $34,509
- WatchPat (Device) $28,770
- OPSUMIT MACITENTAN (Drug) $15,677
- OPSUMIT (Drug) $9,686
- WatchPAT (Device) $9,600
- WINREVAIR (Biological) $9,131
- LOKELMA (Drug) $8,602
- Renal - PD (Device) $5,544
- GENERAL - THERAPIES (Device) $4,903
- Ozempic (Drug) $4,520
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Greensboro
Dr. Michael Wert, M.d, M.D
Internal Medicine — Payments: $439,242
Internal Medicine $439,242
Mark Russo, Md, MD
Internal Medicine — Payments: $318,372
Internal Medicine $318,372
Julian Hutchins, Md, MD
Internal Medicine — Payments: $222,266
Internal Medicine $222,266
Dr. James Beekman, Md, MD
Internal Medicine — Payments: $116,445
Internal Medicine $116,445
Walter Pharr, M.d, M.D
Internal Medicine — Payments: $53,823
Internal Medicine $53,823
Murali Ramaswamy, Md Faafp, MD FAAFP
Internal Medicine — Payments: $45,364
Internal Medicine $45,364